Newest studies

State Department of Motor Vehicles Reporting Mandates of Dementia Diagnoses and Dementia Underdiagnosis

54/100 ✓ Peer-reviewed Health systems and care delivery JAMA Network Open

Key finding: Four states have clinician reporting mandates, 14 have mandates requiring drivers to self-report dementia diagnoses, and 32 states and the District of Columbia do not have explicit requirements. +4 more findings

• Policy

Full summary, score breakdown and related studies → Original source

Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?

47/100 ✓ Peer-reviewed Drug development Neuropharmacology

Key finding: However, a group of drugs from the Glucagon-like peptide-1 (GLP-1) class have shown impressive improvements in clinical phase II trials. +3 more findings

• Treatments
• Clinical Trials
• Other Dementias

Full summary, score breakdown and related studies → Original source

Lithium Therapy's Potential to Lower Dementia Risk and the Prevalence of Alzheimer's Disease: A Meta-Analysis

77/100 ✓ Peer-reviewed Drug development European neurology

Key finding: The forest plot results showed that taking lithium therapy reduced the risk of AD (RR 0.59, 95% confidence interval [CI]: 0.44-0.78) and is also protective in reducing the risk of dementia (RR 0.66, 95% CI: 0.56-0.77). +3 more findings

• Treatments
• Risk Factors
• Prevention

Full summary, score breakdown and related studies → Original source

Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer's disease

43/100 ✓ Peer-reviewed TREM2 and immune genetics Molecular neurodegeneration

Key finding: We proved their efficacy in human iPSC microglia in vitro, as well as their pharmacological activity in vivo in a xenografted microglia model. +2 more findings

• Brain Biology
• Genetics

Full summary, score breakdown and related studies → Original source

Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology

43/100 ✓ Peer-reviewed Biomarkers Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists

Key finding: Whereas plasma NfL has shown promise as a non-specific marker of neuronal injury, plasma pTau181, pTau217, pTau231, and GFAP have demonstrated desirable levels of sensitivity and specificity for identification of individuals with Alzheimer's disease pathology and Alzheimer's dementia. +1 more finding

• Biomarkers

Full summary, score breakdown and related studies → Original source

Alzheimer's disease drug development pipeline: 2024

55/100 ✓ Peer-reviewed Drug development Alzheimer's & dementia (New York, N. Y.)

Key finding: Compared to the 2023 pipeline, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), fewer new chemical entities (88 vs. 101), and a similar number of repurposed agents (39 vs. 40). +2 more findings

• Treatments
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Nogo-A Drives Alzheimer's Disease Progression by Inducing Tauopathy Vulnerability

43/100 ✓ Peer-reviewed Disease mechanisms Aging and disease

Key finding: Here, to gain more comprehensive insights into the impact of Nogo-A on tau protein expression, we showed that Nogo-A induces tau hyperphosphorylation, synapse loss and cognitive dysfunction. +2 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Hidden dangers: Does multisensory impairments accompanying visual impairment increase dementia risk

77/100 ✓ Peer-reviewed Risk factors Journal of psychiatric research

Key finding: Subjects experiencing multisensory impairments concurrent with visual impairment demonstrated a negative association with cognitive function. +4 more findings

• Risk Factors

Full summary, score breakdown and related studies → Original source

Associations of Serum Isoleucine with Mild Cognitive Impairment and Alzheimer's Disease

35/100 ✓ Peer-reviewed Tau biomarkers Annals of geriatric medicine and research

Key finding: Most branched-chain amino acids, except isoleucine (Ile), are correlated with both mild cognitive impairment (MCI) and AD. +3 more findings

• Early Stage

Full summary, score breakdown and related studies → Original source

A disease similarity approach identifies short-lived Niemann-Pick type C disease mice with accelerated brain aging as a novel mouse model for Alzheimer’s disease and aging research

16/100 ⚠ Preprint — not yet peer-reviewed Down syndrome and Alzheimer's bioRxiv

Key finding: Alois Alzheimer, Alzheimer’s disease (AD) has been the most common type of dementia. +3 more findings

• Brain Biology

Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Neuroinflammation induced by amyloid-forming pancreatic amylin: Rationale for a mechanistic hypothesis

43/100 ✓ Peer-reviewed Inflammation and the immune system Biophysical chemistry

Key finding: Data from multiple research teams indicate higher amylin concentrations are associated with increased frequency of cognitive impairment and amylin co-aggregates with β-amyloid in AD-type dementia. +1 more finding

• Brain Biology

Full summary, score breakdown and related studies → Original source

Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial

84/100 ✓ Peer-reviewed Prevention trials Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: The APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (β = -0.27, p = 0.001), greater amyloid deposition (β = 0.48, p = 0.001), 2-year decline in hippocampus (β = -0.27, p = 0.01), total gray matter volume (β = -0.25, p = 0.01), and cortical thickness (β = -0.28, p = 0.003). +4 more findings

• Genetics
• Brain Scans
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Dual Drug Repurposing: The Example of Saracatinib

43/100 ✓ Peer-reviewed Drug development International journal of molecular sciences

Key finding: Despite the promising pre-clinical results and the tolerability shown in phase I trials, where a maximum tolerated dose of 175 mg was defined, phase II clinical data demonstrated a low therapeutic action against several cancers and an elevated rate of adverse effects. +2 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Japan-Multimodal Intervention Trial for the Prevention of Dementia: A randomized controlled trial

84/100 ✓ Peer-reviewed Prevention trials Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: The multidomain intervention showed no efficacy in preventing cognitive decline. +1 more finding

• Clinical Trials
• Prevention
• Genetics

Full summary, score breakdown and related studies → Original source

Biomimetic Nanovesicles as a Dual Gene Delivery System for the Synergistic Gene Therapy of Alzheimer's Disease

50/100 ✓ Peer-reviewed TREM2 and immune genetics ACS nano

Key finding: Additionally, the pathogenesis of AD is intricate and a single drug may not be enough to achieve a satisfactory therapeutic outcome. +3 more findings

• Genetics
• Treatments

Full summary, score breakdown and related studies → Original source

Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease

77/100 ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Multivariable models (p-tau+GFAP+NfL) had the best performance to detect Aβ+ in NormCog (ROCAUC = 0.87) and ImpCog (ROCAUC = 0.87). +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Molecular mechanisms linking type 2 diabetes mellitus and late-onset Alzheimer's disease: A systematic review and qualitative meta-analysis

58/100 ✓ Peer-reviewed Inflammation and the immune system Neurobiology of disease

Key finding: Overall accumulated results highlight insulin signalling, inflammation and inflammasome pathways, proteolysis, gluconeogenesis and glycolysis, glycosylation, lipoprotein metabolism and oxidation, cell cycle regulation or survival, autophagic-lysosomal pathways, and energy. +1 more finding

• Brain Biology
• Genetics
• Risk Factors

Full summary, score breakdown and related studies → Original source

Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review

71/100 ✓ Peer-reviewed Treatments Medicine

Key finding: All drugs improved the cognitive function, with the effect value ranging from -1.23 (95% CI -2.17 to -0.30) for 20 mg memantine to -3.29 (95% CI -4.14 to -2.45) for 32 mg galantamine. +4 more findings

• Treatments
• Side Effects

Full summary, score breakdown and related studies → Original source

Brain and Blood Transcriptome-Wide Association Studies Identify Five Novel Genes Associated with Alzheimer's Disease

82/100 ✓ Peer-reviewed Genetics Journal of Alzheimer's disease : JAD

Key finding: We identified and validated five novel gene associations in cortical brain tissue ( PRKAG1 , C3orf62 , LYSMD4 , ZNF439 , SLC11A2 ) and six genes proximal to known AD-related GWAS loci (Blood: MYBPC3 ; Brain: MTCH2 , CYB561 , MADD , PSMA5 , ANXA11 ). +2 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Single-Cell Gene-Regulatory Networks of Advanced Symptomatic Atherosclerosis

53/100 ✓ Peer-reviewed TREM2 and immune genetics Circulation research

Key finding: Single-cell RNA sequencing data generated with SmartSeq2 (≈8000 genes/cell) in 16 588 single cells isolated during atherosclerosis progression in Ldlr -/- Apob 100/100 mice with human-like plasma lipoproteins and from humans with asymptomatic and symptomatic carotid plaques was clustered into multiple subtypes. +3 more findings

• Genetics
• Policy

Full summary, score breakdown and related studies → Original source

Creating Cultural and Lifestyle Awareness About Dementia and Co-morbidities

43/100 ✓ Peer-reviewed Disparities Journal of Alzheimer's disease reports

Key finding: Therefore, it is high time for all of us to create awareness about dementia in society, particularly among Hispanics/Latinos, Native Americans, and African Americans. +4 more findings

• Health Equity
• Lifestyle
• Risk Factors

Full summary, score breakdown and related studies → Original source

Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain

54/100 ✓ Peer-reviewed TREM2 and immune genetics Nature neuroscience

Key finding: Microglia, and specifically those expressing the AD risk gene TREM2, are considered important players in AD, but their exact contribution to pathology remains unclear. +3 more findings

• Brain Biology
• Genetics

Full summary, score breakdown and related studies → Original source

MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial

88/100 ✓ Peer-reviewed Clinical trials Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Forty-four participants were recruited between September 2019 and June 2022. +4 more findings

• Clinical Trials
• Brain Biology
• Other Dementias

Full summary, score breakdown and related studies → Original source

Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial

62/100 ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: These results suggest that prevalence of brain amyloid pathology differed, but that eligibility based on plasma was equally effective across racial and ethnic group members. +2 more findings

• Biomarkers
• Health Equity
• Early Stage

Full summary, score breakdown and related studies → Original source

Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study

76/100 ✓ Peer-reviewed Treatments BMJ

Key finding: Antipsychotic use compared with non-use in adults with dementia was associated with increased risks of stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia, and acute kidney injury, but not ventricular arrhythmia. +4 more findings

• Treatments
• Side Effects

Full summary, score breakdown and related studies → Original source